Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan M Weiss

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Annals of Hematology|March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDAKenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
The Journal of Clinical Investigation|March 22, 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaAdam D Cohen, Alfred L Garfall, Edward A Stadtmauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood Cancer Journal|October 17, 2020
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, et al.
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
American Journal of Hematology|March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA studyVaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Nature Reviews. Nephrology|December 5, 2018
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research GroupNelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Annals of Hematology|March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDAKenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
The Journal of Clinical Investigation|March 22, 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaAdam D Cohen, Alfred L Garfall, Edward A Stadtmauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood Cancer Journal|October 17, 2020
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, et al.
Lancet (London, England)|January 19, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialSagar Lonial, Brendan M Weiss, Saad Z Usmani, et al.
American Journal of Hematology|March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA studyVaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Nature Reviews. Nephrology|December 5, 2018
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research GroupNelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Pageof 6